Soluble Urokinase Plasminogen Activator Receptor (suPAR) Concentrations Are Elevated in Patients with Neuroendocrine Malignancies

Soluble Urokinase Plasminogen Activator Receptor (suPAR) Concentrations Are Elevated in Patients with Neuroendocrine Malignancies

Neuroendocrine neoplasia (NEN) comprises heterogeneous tumors that are challenging to diagnose and, especially in cases of poorly differentiated (G3) NEN, are associated with very limited survival. Novel biomarkers allowing an early diagnosis as well as an optimal selection of suitable treatment opt...

Full description

Bibliographic Details
Main Authors:	Burcin Özdirik, Anna Stueven, Jana Knorr, Lukas Geisler, Raphael Mohr, Münevver Demir, Teresa Hellberg, Sven H. Loosen, Fabian Benz, Bertram Wiedenmann, Frank Tacke, Alexander Wree, Henning Jann, Christoph Roderburg
Format:	Article
Language:	English
Published:	MDPI AG 2020-05-01
Series:	Journal of Clinical Medicine
Subjects:	soluble urokinase-type plasminogen activator receptor neuroendocrine tumor neuroendocrine carcinoma biomarker survival
Online Access:	https://www.mdpi.com/2077-0383/9/6/1647

Similar Items

Analysis of miR-29 Serum Levels in Patients with Neuroendocrine Tumors—Results from an Exploratory Study
by: Burcin Özdirik, et al.
Published: (2020-09-01)

Serum Levels of Urokinase Plasminogen Activator Receptor (suPAR) Discriminate Moderate Uncontrolled from Severe Asthma
by: Ourania S. Kotsiou, et al.
Published: (2022-10-01)

Soluble Urokinase Plasminogen Activator Receptor (suPAR) in the Emergency Department (Ed): A Tool for the Assessment of Elderly Patients
by: Ria M. Holstein, et al.
Published: (2022-06-01)

Evaluation of Urokinase Plasminogen Activator Receptor, Soluble Urokinase Plasminogen Activator Receptor, and β1 Integrin in Patients with Hodgkin′s Lymphoma
by: Shirin Kouhpayeh, et al.
Published: (2017-01-01)

Monitoring of chemotherapy successfulness of Platina/Taxol chemotherapy protocol by using determination of serum urokinase plasminogen activator (uPA) and soluble urokinase plasminogen activator receptor (suPAR) in patients with ovarian carcinoma FIGO II
by: Dženita Ljuca, et al.
Published: (2007-05-01)

Soluble Urokinase Plasminogen Activator Receptor Levels Are Associated with Severity of Fibrosis in Patients with Primary Sclerosing Cholangitis
by: Burcin Özdirik, et al.
Published: (2022-04-01)

Soluble Urokinase Plasminogen Activator Receptor and Venous Thromboembolism in COVID‐19
by: Shengyuan Luo, et al.
Published: (2022-09-01)

The Contribution of the Urokinase Plasminogen Activator and the Urokinase Receptor to Pleural and Parenchymal Lung Injury and Repair: A Narrative Review
by: Torry A. Tucker, et al.
Published: (2021-02-01)

Specific inhibitors of urokinase plasminogen activator for treatment of cancers; In silico approach
by: Benjamin Talbot, et al.
Published: (2020-05-01)

Value of soluble Urokinase plasminogen activator receptor over age as a biomarker of impaired myocardial relaxation
by: Koh, Angela S., et al.
Published: (2018)

Reduced Expression of Urokinase Plasminogen Activator in Brown Adipose Tissue of Obese Mouse Models
by: Chung-Ze Wu, et al.
Published: (2021-03-01)

Urokinase plasminogen activator (uPA) and plasminogen activator inhibitor type-1 (PAI-1) in breast cancer - correlation with traditional prognostic factors
by: Lampelj Maja, et al.
Published: (2015-12-01)

Urokinase-type plasminogen activator is a modulator of synaptic plasticity in the central nervous system: implications for neurorepair in the ischemic brain
by: Manuel Yepes
Published: (2020-01-01)

Macrophages and Urokinase Plasminogen Activator Receptor System in Multiple Myeloma: Case Series and Literature Review
by: Paola Manzo, et al.
Published: (2023-06-01)

The diagnostic value of soluble urokinase-type plasminogen activator receptor (suPAR) for the discrimination of vertebral osteomyelitis and degenerative diseases of the spine
by: Jan Simon Scharrenberg, et al.
Published: (2019-11-01)

Concentrations of plasminogen activator inhibitor-1 (PAI-1) and urokinase plasminogen activator (uPA) in induced sputum of asthma patients after allergen challenge
by: Krzysztof Kowal,, et al.
Published: (2010-04-01)

Predicting Mortality in African Americans With Type 2 Diabetes Mellitus: Soluble Urokinase Plasminogen Activator Receptor, Coronary Artery Calcium, and High‐Sensitivity C‐Reactive Protein
by: Salim S. Hayek, et al.
Published: (2018-05-01)

The Urokinase Plasminogen Activation System in Pancreatic Cancer: Prospective Diagnostic and Therapeutic Targets
by: Ashna A. Kumar, et al.
Published: (2022-01-01)

QSAR modelling to predict structural features of certain sulfonamide as Urokinase-type Plasminogen Activator inhibitors
by: Rahul D. Jawarkar, et al.
Published: (2024-06-01)

Inhibitory effects of wogonin on invasion by human oral cancer cells by decreasing the activity of matrix metalloproteinases and urokinase-plasminogen activator
by: Yung-Chuan Ho, et al.
Published: (2014-06-01)

The Prognostic Significance of Soluble Urokinase Plasminogen Activator Receptor in Acute Myeloid Leukemia
by: Nergiz Erkut, et al.
Published: (2016-05-01)

Soluble Urokinase-Type Plasminogen Activator Receptor (suPAR) Is a Biomarker Associated with Left Ventricular Hypertrophy in the Elderly, Specifically in Women
by: Rafał Nikodem Wlazeł, et al.
Published: (2023-05-01)

Urokinase-type plasminogen activator and plasminogen activator inhibitor-1 complex as a serum biomarker for COVID-19
by: Tetiana Yatsenko, et al.
Published: (2024-01-01)

Corrigendum: Urokinase-type plasminogen activator and plasminogen activator inhibitor-1 complex as a serum biomarker for COVID-19
by: Tetiana Yatsenko, et al.
Published: (2024-03-01)

Soluble urokinase plasminogen activator receptor and its complicated role in hemodialysis (HD) patients with Covid-19 infection
by: Ioannis Griveas, et al.
Published: (2021-07-01)

Inflammatory Cytokines Associated with Diagnosis, Tumor Grade and Prognosis in Patients with Neuroendocrine Tumors
by: Lukas Geisler, et al.
Published: (2022-10-01)

Association between serum soluble urokinase-type plasminogen activator receptor and atrial fibrillation
by: Noboru Ichihara, et al.
Published: (2017-10-01)

Local Production of Soluble Urokinase Plasminogen Activator Receptor and Plasminogen Activator Inhibitor‐1 in the Coronary Circulation Is Associated With Coronary Endothelial Dysfunction in Humans
by: Michel T. Corban, et al.
Published: (2018-08-01)

Experimental and Clinical Evidence Supports the Use of Urokinase Plasminogen Activation System Components as Clinically Relevant Biomarkers in Gastroesophageal Adenocarcinoma
by: Gary Tincknell, et al.
Published: (2021-08-01)

Exogenous Urokinase Inhibits Proteasomal Degradation of Its Cognate Urokinase Plasminogen Activator Receptor
by: Ran Zhu, et al.
Published: (2022-08-01)

Admission levels of Soluble Urokinase Plasminogen Activator Receptor (suPAR) are Associated with the Development of Severe Complications in Hospitalised COVID-19 Patients: A Prospective Cohort Study
by: Abderrahim Oulhaj, et al.
Published: (2021-06-01)

Can serum soluble urokinase plasminogen activator receptor be an effective biomarker in comparing the inflammatory response between laparoscopic and open appendectomy?
by: Basak Erginel, et al.
Published: (2023-06-01)

Urokinase-type Plasminogen Activator and Plasminogen Activator Inhibitor Induction by Etoposide in a Glioblastoma Cell Strain
by: Branko Brdar, et al.
Published: (2002-01-01)

Fibrinolysis regulation by platelets retaining plasminogen and tissue-type plasminogen activator on their surface
by: T. Grinenko, et al.
Published: (2019-12-01)

Simulated in vitro hypoxic conditions from psoriatic arthritis cartilage change plasminogen activating system urokinase and serpine functionality. Reversal of antiapoptotic protection suggests common homeostatic buffering
by: Michal Nohawica, et al.
Published: (2022-02-01)

The Urokinase-Type Plasminogen Activator Contributes to cAMP-Induced Steroidogenesis in MA-10 Leydig Cells
by: Zoheir B. Demmouche, et al.
Published: (2022-07-01)

Urokinase vs Tissue-Type Plasminogen Activator for Thrombolytic Evacuation of Spontaneous Intracerebral Hemorrhage in Basal Ganglia
by: Yuqian Li, et al.
Published: (2017-08-01)

Multifaceted Role of the Urokinase-Type Plasminogen Activator (uPA) and Its Receptor (uPAR): Diagnostic, Prognostic, and Therapeutic Applications
by: Niaz Mahmood, et al.
Published: (2018-02-01)

Soluble urokinase-type plasminogen activator receptor as a biomarker of treatment response in childhood tuberculosis
by: Ery Olivianto, et al.
Published: (2019-01-01)

Clinical value of soluble urokinase-type plasminogen activator receptor in predicting sepsis-associated acute kidney injury
by: Wenwen Zhang, et al.
Published: (2024-12-01)